Sanofi's Multiple Sclerosis Drug Approved in Europe After FDA Rejection
A multiple sclerosis treatment from Sanofi has received a positive review in Europe, marking a notable shift after its rejection by the FDA last year.
Editorial Staff
1 min read
Updated 15 days ago
Sanofi's drug for multiple sclerosis faced a setback when it was rejected by the FDA late last year. This decision raised concerns about the medication's future.
However, the drug has now received a positive review in Europe, indicating a more favorable reception across the Atlantic.
This approval represents a significant turnaround for Sanofi, potentially opening new avenues for patients in need of effective treatments for multiple sclerosis.